Global Health Developments: New Approvals, Outages, and Outbreaks

This summary provides recent health news, covering Eli Lilly's weight loss drug approval in China, German hospitals canceling operations due to a global IT outage, and NHS disruptions caused by a cyberattack. Additional topics include Boehringer's Humira rival discount, Canadian health challenges, bird flu cases in Colorado, Abbott's glucose monitors, and Brazil halting poultry exports due to Newcastle disease.

In recent health news, Eli Lilly announced that China's regulators have approved its weight loss drug, tirzepatide. This approval intensifies Eli Lilly's competition with Novo Nordisk in the Asian market. The announcement saw a 1.6% rise in the company's shares, trading at $862.39.

Two German hospitals in Luebeck and Kiel canceled elective operations due to a global IT outage linked to the cybersecurity firm Crowdstrike. Meanwhile, England's NHS reported disruptions in scheduling and patient records due to the same outage, although emergency services were unaffected.

In the U.S., Boehringer Ingelheim and GoodRx have partnered to offer a cheaper alternative to Humira, available at a 92% discount. Similarly, Abbott announced a marketing push for its new glucose monitoring device, aiming to reach non-diabetic users. Additionally, the U.S. CDC confirmed two new bird flu cases in Colorado, while Brazil halted some poultry exports following a Newcastle disease case.

(With inputs from agencies.)